Effect of Icosapent Ethyl on Gynoid Fat and Bone Mineral Health in the Metabolic Syndrome: A Preliminary Report |
| |
| Institution: | 1. Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA;2. Baltimore VA Geriatric Research, Education and Clinical Center, Baltimore, MD, USA;3. Department of Medicine, Georgetown University School of Medicine, Washington, DC, USA;1. Institute for Neurosciences, St. Luke''s Medical Center- Global City, Manila, Philippines;2. Heart Institute, St. Luke''s Medical Center- Global City, Manila, Philippines;1. Cardiac MR PET CT Program, Massachusetts General Hospital and Harvard Medical School, 165 Cambridge Street, Suite 400, Boston, MA 02114, USA;2. Cardiology Division, Evanston Hospital, Walgreen Building 3rd Floor, 2650 Ridge Ave, Evanston, IL 60201, USA;3. Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany;4. Biostatistics Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA;5. Department of Clinical Radiology, Klinikum Grosshadern, Ludwig Maximilians University, Munich, Germany;6. Department of Emergency Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA;7. Dalio Institute of Cardiovascular Imaging, New York-Presbyterian Hospital, Weill Cornell Medical College, NY, USA |
| |
| Abstract: | PurposeThe metabolic syndrome (MetS) is a systemic disorder associated with reduced atheroprotective gynoid fat and bone mineral content (BMC). The goal of this pilot study was to assess whether administration of icosapent ethyl (IPE), a purified formulation of eicosapentaenoic acid, would maintain gynoid fat and BMC over a 9-month treatment period.MethodsPatients with MetS aged ≥40 years were randomly assigned to receive 4 g daily of IPE (2 g BID with food) or placebo (paraffin oil 2 g BID with food) for 9 months. Data were collected at baseline and 9 months later. The data included anthropometric measures, biochemical analysis, and whole body fat mass, including gynoid fat. Bone mineral density and BMC were measured by using dual-energy X-ray absorptiometry. A two-tailed P value ≤ 0.05 was considered statistically significant.FindingsThe study sample consisted of 13 patients with MetS (mean age, 61.6 years; age range, 44–77 years; 77% female and 23% male). Compared with the IPE group, the placebo group experienced statistically significant mean reductions in percent gynoid fat (pre/post, 46.8%–43.5%; P = 0.02), BMC (pre/post, 2461 g–2423 g; P = 0.02), and bone mineral density (pre/post, 1.24 g/cm2 to 1.22 g/cm2; P = 0.05) over the 9-month study period.ImplicationsThe results of this pilot study raise the possibility that IPE supplementation may preserve gynoid fat distribution and bone mineral health in patients with MetS. Larger, randomized longitudinal studies are necessary to determine the potential long-term metabolic benefits of IPE treatment. |
| |
| Keywords: | bone mineral health gynoid fat hypertriglyceridemia icosapent ethyl metabolic syndrome |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
